Target
MAP kinase-activated protein kinase 5
Ligand
BDBM50193995
Substrate
n/a
Meas. Tech.
ChEMBL_542069 (CHEMBL1016938)
IC50
>10000±n/a nM
Citation
 Changelian, PSFlanagan, MEBall, DJKent, CRMagnuson, KSMartin, WHRizzuti, BJSawyer, PSPerry, BDBrissette, WHMcCurdy, SPKudlacz, EMConklyn, MJElliott, EAKoslov, ERFisher, MBStrelevitz, TJYoon, KWhipple, DASun, JMunchhof, MJDoty, JLCasavant, JMBlumenkopf, TAHines, MBrown, MFLillie, BMSubramanyam, CShang-Poa, CMilici, AJBeckius, GEMoyer, JDSu, CWoodworth, TGGaweco, ASBeals, CRLittman, BHFisher, DASmith, JFZagouras, PMagna, HASaltarelli, MJJohnson, KSNelms, LFDes Etages, SGHayes, LSKawabata, TTFinco-Kent, DBaker, DLLarson, MSi, MSPaniagua, RHiggins, JHolm, BReitz, BZhou, YJMorris, REO'Shea, JJBorie, DC Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302:875-878 (2003) [PubMed]  Article 
Target
Name:
MAP kinase-activated protein kinase 5
Synonyms:
MAP kinase-activated protein kinase 5 (PRAK) | MAPK-Activated Protein Kinase 5 (MK5) | MAPK-activated protein kinase 5 | MAPK5_HUMAN | MAPKAP kinase 5 | MAPKAPK5 | PRAK | p38-regulated/activated protein kinase | p38-regulated/activated protein kinase (PRAK)
Type:
Serine/threonine-protein kinase
Mol. Mass.:
54229.92
Organism:
Homo sapiens (Human)
Description:
Recombinant MAPKAPK5 was phosphorylated by incubation with active p38alpha before assays.
Residue:
473
Sequence:
MSEESDMDKAIKETSILEEYSINWTQKLGAGISGPVRVCVKKSTQERFALKILLDRPKARNEVRLHMMCATHPNIVQIIEVFANSVQFPHESSPRARLLIVMEMMEGGELFHRISQHRHFTEKQASQVTKQIALALRHCHLLNIAHRDLKPENLLFKDNSLDAPVKLCDFGFAKIDQGDLMTPQFTPYYVAPQVLEAQRRHQKEKSGIIPTSPTPYTYNKSCDLWSLGVIIYVMLCGYPPFYSKHHSRTIPKDMRRKIMTGSFEFPEEEWSQISEMAKDVVRKLLKVKPEERLTIEGVLDHPWLNSTEALDNVLPSAQLMMDKAVVAGIQQAHAEQLANMRIQDLKVSLKPLHSVNNPILRKRKLLGTKPKDSVYIHDHENGAEDSNVALEKLRDVIAQCILPQAGKGENEDEKLNEVMQEAWKYNRECKLLRDTLQSFSWNGRGFTDKVDRLKLAEIVKQVIEEQTTSHESQ
  
Inhibitor
Name:
BDBM50193995
Synonyms:
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile | 3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile | 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile | CHEMBL221959 | CP-690550 | TOFACITINIB CITRATE | Tofacitinib | Tofacitinib citrate (1) | US10112907, Example 00035 | US10399979, Compound Tofacitinib | US10766894, Compound TABLE 1.20 | US10875847, Compound Tofacitinib | US11078206, Example Tofacitinib | US11203595, TABLE 1.20 | US11339167, Example Tofacitinib
Type:
Small organic molecule
Emp. Form.:
C16H20N6O
Mol. Mass.:
312.3696
SMILES:
C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N |r|
Structure:
Search PDB for entries with ligand similarity: